MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-24-2026
Curis ROCE Ratio 2011-2026 | CRIS
Annual ROCE Ratio Curis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -104.6 | 742.61 | -245.71 | -113.89 | -46.37 | -19.05 | -85.26 | -121.64 | -83.36 | -90.6 | -38.16 | -30.19 | -12.72 | -13.86 | -16.22 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 742.61 | -245.71 | -18.6 |
Quarterly ROCE Ratio Curis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 380.83 | 454.67 | 2198.56 | 1792.08 | 1750.28 | 1587.51 | -261.66 | -119.86 | -142.47 | -123.29 | -101.28 | -66.81 | -76.57 | -63.72 | -48.92 | -26.45 | -31.25 | -25.09 | -19.78 | -19.05 | 7.38 | 26.68 | 48.94 | 71.82 | 164.7 | 291.73 | 448.44 | 652.42 | 508.22 | 305.18 | 75.72 | -207.39 | -214.23 | -248.87 | -230.73 | -198.08 | -182.07 | -94.63 | -69.56 | -87.55 | -83.17 | -91.62 | -85.39 | -53.26 | -47.03 | -30.78 | -27.16 | -20.84 | -25.4 | -40.16 | -45.68 | -15.14 | -27.22 | -24.82 | -29.32 | -37.03 | -12.08 | -11.58 | -13.37 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2198.56 | -261.66 | 125.17 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B |  Britain |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Celldex Therapeutics
CLDX
|
-54.51 | $ 34.55 | 2.04 % | $ 2.29 B |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 4.47 | 12.59 % | $ 10.8 B |  Australia |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Akari Therapeutics, Plc
AKTX
|
-60.98 | $ 5.8 | 13.28 % | $ 391 B | Britain |
 |
Aligos Therapeutics
ALGS
|
-164.32 | $ 6.68 | -12.79 % | $ 66 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
63.56 | $ 309.66 | -3.27 % | $ 40.6 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 22.88 | 4.91 % | $ 1.07 B | USA |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 102.92 | 0.78 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.04 | -1.3 % | $ 5 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
BioXcel Therapeutics
BTAI
|
52.86 | $ 1.15 | 7.48 % | $ 14 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
72.06 | $ 1.41 | 4.07 % | $ 363 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.32 | 1.41 % | $ 462 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 24.53 | 1.41 % | $ 3.12 B | USA |
 |
Burford Capital Limited
BUR
|
14.24 | $ 4.96 | 6.1 % | $ 792 M | Britain |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Cabaletta Bio
CABA
|
-153.72 | $ 3.44 | -2.27 % | $ 346 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.6 | -0.62 % | $ 426 M | Britain |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-59.93 | $ 0.86 | 0.39 % | $ 5.79 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
-107.83 | - | - | $ 1.41 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |